Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ALPK1 agonist PTT-936

An orally bioavailable innate immune agonist and activator of the cytosolic alpha-protein kinase 1 (ALPK1) that is an ADP-heptose derived from bacteria, with potential immunomodulating and antineoplastic activities. Upon oral administration, ALPK1 agonist PTT-936, being a ADP-heptose, specifically targets and binds to ALPK1, thereby activating the ALPK1-mediated signal transduction pathway. This initiates the phosphorylation of TRAF-interacting protein with forkhead-associated domain (TIFA), leading to the activation of pro-inflammatory nuclear factor kappa-B (NF-kB) signaling, cytokine induction and the activation and recruitment of immune cells, such as natural killer (NK) cells and T cells. This leads to tumor cell eradication and inhibits tumor cell proliferation. ALPK1, a bacterial pattern recognition receptor (PPR), is involved in bacterial pathogen recognition and plays a key role in innate immune defenses against bacterial infection. It recognizes ADP-heptose, a metabolite released during the biosynthesis and degradation of lipopolysaccharides (LPS), which is present in bacteria but not present in mammalian cells.
Synonym:alpha-protein kinase 1 agonist PTT-936
ALPK1 activator PTT-936
chromosome 4 kinase agonist PTT-936
lymphocyte alpha-protein kinase agonist PTT-936
Code name:PTT 936
PTT-936
PTT936
Search NCI's Drug Dictionary